Forendo Pharma has appointed David Colpman as a non-executive director to its board of directors, the private Finnish company disclosed on Wednesday.

Colpman has over 25 years of experience in pharma and biotech business development and strategy.

He recently served as head of Global Business Development at Shire (LON: SHP). His previous positions included business and commercial positions at Glaxo Wellcome and Novo Nordisk (CPH: NOVO-B).

Colpman also serves on the boards of Orexo AB (STO: ORX) and HRA Pharma Ltd.

Forendo Pharma currently focuses on the development of tissue-specific hormone inhibitors to rebalance local oestrogen metabolism in endometriosis lesions.